209 related articles for article (PubMed ID: 32999002)
1. An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression.
Sainson RCA; Thotakura AK; Kosmac M; Borhis G; Parveen N; Kimber R; Carvalho J; Henderson SJ; Pryke KL; Okell T; O'Leary S; Ball S; Van Krinks C; Gamand L; Taggart E; Pring EJ; Ali H; Craig H; Wong VWY; Liang Q; Rowlands RJ; Lecointre M; Campbell J; Kirby I; Melvin D; Germaschewski V; Oelmann E; Quaratino S; McCourt M
Cancer Immunol Res; 2020 Dec; 8(12):1568-1582. PubMed ID: 32999002
[TBL] [Abstract][Full Text] [Related]
2. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.
Metzger TC; Long H; Potluri S; Pertel T; Bailey-Bucktrout SL; Lin JC; Fu T; Sharma P; Allison JP; Feldman RM
Cancer Res; 2016 Jul; 76(13):3684-9. PubMed ID: 27197182
[TBL] [Abstract][Full Text] [Related]
3. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.
Faget J; Bendriss-Vermare N; Gobert M; Durand I; Olive D; Biota C; Bachelot T; Treilleux I; Goddard-Leon S; Lavergne E; Chabaud S; Blay JY; Caux C; Ménétrier-Caux C
Cancer Res; 2012 Dec; 72(23):6130-41. PubMed ID: 23026134
[TBL] [Abstract][Full Text] [Related]
4. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of CD4+ T cells in the decision between tolerance and immunity in vivo reveals a pivotal role for ICOS.
Lischke T; Hegemann A; Gurka S; Vu Van D; Burmeister Y; Lam KP; Kershaw O; Mollenkopf HJ; Mages HW; Hutloff A; Kroczek RA
J Immunol; 2012 Jul; 189(1):234-44. PubMed ID: 22661090
[TBL] [Abstract][Full Text] [Related]
6. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
7. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
[TBL] [Abstract][Full Text] [Related]
8. KLRG1 expression identifies short-lived Foxp3
Kornete M; Mason E; Istomine R; Piccirillo CA
Autoimmunity; 2017 Sep; 50(6):354-362. PubMed ID: 28850267
[TBL] [Abstract][Full Text] [Related]
9. Immuno-PET Monitoring of CD8
Alsaid H; Cheng SH; Bi M; Xie F; Rambo M; Skedzielewski T; Hoang B; Mohanan S; Comroe D; Gehman A; Hsu CY; Farhangi K; Tran H; Sherina V; Doan M; Groseclose MR; Hopson CB; Brett S; Wilson IA; Nicholls A; Ballas M; Waight JD; Jucker BM
Mol Imaging Biol; 2023 Jun; 25(3):528-540. PubMed ID: 36266600
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS- regulatory T cells.
Zhang S; Yong LK; Li D; Cubas R; Chen C; Yao Q
PLoS One; 2013; 8(7):e68303. PubMed ID: 23874581
[TBL] [Abstract][Full Text] [Related]
11. Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression.
Strauss L; Bergmann C; Szczepanski MJ; Lang S; Kirkwood JM; Whiteside TL
J Immunol; 2008 Mar; 180(5):2967-80. PubMed ID: 18292519
[TBL] [Abstract][Full Text] [Related]
12. Th1-Like ICOS+ Foxp3+ Treg Cells Preferentially Express CXCR3 and Home to β-Islets during Pre-Diabetes in BDC2.5 NOD Mice.
Kornete M; Mason ES; Girouard J; Lafferty EI; Qureshi S; Piccirillo CA
PLoS One; 2015; 10(5):e0126311. PubMed ID: 25946021
[TBL] [Abstract][Full Text] [Related]
13. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
Solinas C; Gu-Trantien C; Willard-Gallo K
ESMO Open; 2020 Jan; 5(1):. PubMed ID: 32516116
[TBL] [Abstract][Full Text] [Related]
14. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
Drerup JM; Deng Y; Pandeswara SL; Padrón ÁS; Reyes RM; Zhang X; Mendez J; Liu A; Clark CA; Chen W; Conejo-Garcia JR; Hurez V; Gupta H; Curiel TJ
Cancer Res; 2020 Nov; 80(22):5063-5075. PubMed ID: 32948605
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating mast cells stimulate ICOS
Lv Y; Tian W; Teng Y; Wang P; Zhao Y; Li Z; Tang S; Chen W; Xie R; Lü M; Zhuang Y
J Adv Res; 2024 Mar; 57():149-162. PubMed ID: 37086778
[TBL] [Abstract][Full Text] [Related]
16. ICOS mediates the generation and function of CD4+CD25+Foxp3+ regulatory T cells conveying respiratory tolerance.
Busse M; Krech M; Meyer-Bahlburg A; Hennig C; Hansen G
J Immunol; 2012 Aug; 189(4):1975-82. PubMed ID: 22815292
[TBL] [Abstract][Full Text] [Related]
17. Suppressive IL-17A
Downs-Canner S; Berkey S; Delgoffe GM; Edwards RP; Curiel T; Odunsi K; Bartlett DL; Obermajer N
Nat Commun; 2017 Mar; 8():14649. PubMed ID: 28290453
[TBL] [Abstract][Full Text] [Related]
18. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
Schofield DJ; Percival-Alwyn J; Rytelewski M; Hood J; Rothstein R; Wetzel L; McGlinchey K; Adjei G; Watkins A; Machiesky L; Chen W; Andrews J; Groves M; Morrow M; Stewart RA; Leinster A; Wilkinson RW; Hammond SA; Luheshi N; Dobson C; Oberst M
MAbs; 2021; 13(1):1857100. PubMed ID: 33397194
[TBL] [Abstract][Full Text] [Related]
19. A subpopulation of CD103(pos) ICOS(pos) Treg cells occurs at high frequency in lymphopenic mice and represents a lymph node specific differentiation stage.
Barthlott T; Bosch AJ; Berkemeier C; Nogales-Cadenas R; Jeker LT; Keller MP; Pascual-Montano A; Holländer GA
Eur J Immunol; 2015 Jun; 45(6):1760-71. PubMed ID: 25752506
[TBL] [Abstract][Full Text] [Related]
20. ICOS
Nagase H; Takeoka T; Urakawa S; Morimoto-Okazawa A; Kawashima A; Iwahori K; Takiguchi S; Nishikawa H; Sato E; Sakaguchi S; Mori M; Doki Y; Wada H
Int J Cancer; 2017 Feb; 140(3):686-695. PubMed ID: 27756099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
